Personalis (PSNL) shares surged 20.5% to $10.28 after announcing new data from AstraZeneca’s lung cancer study, showcasing the effectiveness of its MRD test. Analysts expect a quarterly loss of $0.28 per share, but trends in earnings estimate revisions suggest potential strength. PSNL holds a Zacks Rank #3 (Hold) in the Medical – Generic Drugs industry. Taysha Gene Therapies (TSHA) closed 4.9% lower at $5.08, with a consensus EPS estimate of -$0.09 for the upcoming report.

Five stocks, including PSNL and TSHA, are projected to double in value according to Zacks experts. These picks have the potential to gain over 100% in the next year, with past recommendations soaring up to +232%. Most stocks in this report are under the radar, presenting an opportunity to invest early. Check out these potential home runs and download the 7 Best Stocks for the Next 30 Days from Zacks Investment Research for free.

Read more at Nasdaq: Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?